Lung Cancer

Racial Disparities in Lung Cancer: Part 2 of a Special Series

By

Tori Rodriguez, MA, LPC, AHC

Publish Date January 12, 2021

In part 2 of this 3-part series, the recent State of Lung Cancer report by the American Lung Association, which included state-level and national-level data on lung cancer in people of color for the first time.

Racial Disparities in Lung Cancer: Part 1 of a Special Series

By

Tori Rodriguez, MA, LPC, AHC

Publish Date January 8, 2021

A sizable body of research has long shown racial disparities in treatment and survival between Black and White patients with lung cancer.

Tepotinib Yields High Partial Response Rates in NSCLC With MET Alterations

By

Agata Boxe

Publish Date October 26, 2020

The MET alteration occurs in 3% to 4% of patients with the condition.

Lung Cancer Screening More Likely in Patients With Comorbid Conditions

The presence of comorbid conditions is associated with a higher likelihood of undergoing lung cancer screening with low-dose computed tomography.

Contralateral Esophagus–Sparing Technique Reduces Risk of Severe Esophagitis in Locally Advanced Lung Cancer

CEST involves contouring the contralateral esophagus as an avoidance structure to guide a steep dose falloff gradient across the esophagus.

Severe Lymphopenia Associated With Shorter PFS in Unresectable, Stage III NSCLC

A single-center, retrospective cohort study was conducted to assess response to treatment and progression of disease in patients with severe lymphopenia undergoing treatment with immune checkpoint inhibitors for NSCLC.

Trial Investigating Canakinumab for Advanced or Metastatic NSCLC Misses Primary Endpoint

Canakinumab is a human monoclonal antibody that binds with high affinity and selectivity to interleukin-1beta.

USPSTF Expands Eligibility for Annual Lung Cancer Screening

The U.S. Preventive Services Task Force recommends annual LDCT screening for lung cancer for high-risk adults aged 50 to 80 years.